SCHEMBL7404185

SCHEMBL7404185

c1ccc(-c2ccc(-c3ccco3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.64
PIK3R1 P27986 1/20 0.55
PIK3CA P42336 1/20 0.55
ALDH1A1 P00352 7/20 0.53
KDM4E B2RXH2 6/20 0.53
HSD17B10 Q99714 4/20 0.53
HPGD P15428 4/20 0.53
NPC1 O15118 2/20 0.53
RAB9A P51151 2/20 0.53
KEAP1 Q14145 1/20 0.50
LPL P06858 1/20 0.48
LIPG Q9Y5X9 1/20 0.48
POLB P06746 4/20 0.47
TSHR P16473 3/20 0.47
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
MAPT P10636 2/20 0.46
PKM P14618 2/20 0.46
ALOX15 P16050 2/20 0.46
CASP1 P29466 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162083 0.95 TAAR1 (0.62) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
SCHEMBL11073018 0.92 TAAR1 (0.60) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
Hydrochloric Acid SCHEMBL8104290 0.92 TAAR1 (0.60) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
SCHEMBL30487922 0.92 TAAR1 (0.73) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
SCHEMBL394300 0.89 TAAR1 (0.76) TAAR1ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL244155 0.87
SCHEMBL28323221 0.84 TAAR1 (0.62) TAAR1ALDH1A1KDM4EHSD17B10HPGD
SCHEMBL27761661 0.84 KEAP1 (0.59) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
SCHEMBL12230533 0.83 TAAR1 (0.52) TAAR1PIK3R1PIK3CAALDH1A1KDM4E
SCHEMBL20324154 0.83 TAAR1 (0.52) TAAR1PIK3R1PIK3CAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114516880-B Method for synthesizing furo [2,3-b ] quinoxaline derivative 桂林理工大学 2023-11-17 CN disclosed
CN-114516880-A Novel method for synthesizing furo [2,3-b ] quinoxaline derivative 桂林理工大学 2022-05-20 CN disclosed
US-10662206-B2 Method for preparing silane derivatives from furan derivatives in presence of borane catalyst INSTITUTE FOR BASIC SCIENCE (KR) 2020-05-26 US disclosed
US-20190263840-A1 METHOD FOR PREPARING SILANE DERIVATIVES FROM FURAN DERIVATIVES IN PRESENCE OF BORANE CATALYST KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2019-08-29 US disclosed
WO-2017204554-A2 METHOD FOR PREPARING SILANE DERIVATIVES FROM FURAN DERIVATIVES IN PRESENCE OF BORANE CATALYST 기초과학연구원 2017-11-30 WO disclosed
US-6495699-B2 ANTIARTHRITIC AGENTS; OSTEOPOROSIS AGOURON PHARMACEUTICALS INC. 2002-12-17 US disclosed
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use BENDER STEVEN L (US) 2002-02-14 US disclosed
US-6306892-B1 ENZYME INHIBITORS HETEROCYCLIC AMIDES AGOURON PHARMACEUTICALS, INC. 2001-10-23 US disclosed
US-6174915-B1 FOR TREATING MAMMALIAN DISEASE CONDITION MEDIATED BY METALLOPROTEINASE ACTIVITY AGOURON PHARMACEUTICALS, INC. 2001-01-16 US disclosed
US-6008243-A AN ENZYME INHIBITOR FOR PREVENTING THE DEGRADATION AND REMODELING OF CONNECTIVE TISSUES AGOURON PHARMACEUTICALS, INC. (US) 1999-12-28 US disclosed
EP-0937042-A1 HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1999-08-25 EP disclosed
WO-1998017643-A1 HETEROARYL SUCCINAMIDES AND THEIR USE AS METALLOPROTEINASE INHIBITORS AGOURON PHARMACEUTICALS, INC. (US) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10662206-B2 Method for preparing silane derivatives from furan derivatives in presence of borane catalyst PFAS, HPD, FDPS TAAR1 4244/4885PIK3R1 3376/4885PIK3CA 1152/4885
US-20190263840-A1 METHOD FOR PREPARING SILANE DERIVATIVES FROM FURAN DERIVATIVES IN PRESENCE OF BORANE CATALYST PFAS, HPD, FDPS TAAR1 4244/4885PIK3R1 3376/4885PIK3CA 1152/4885
US-20020019429-A1 Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use MMP9, MMP2, MMP3 TAAR1 4474/4885PIK3R1 2592/4885PIK3CA 2538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.